Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Efficacy of MH004 Cream in Healthy Volunteers and Patients with Atopic Dermatitis or Rheumatoid Arthritis
NCT04815148Phase 1Unknown
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Apr 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of INN-04-01 in atopic dermatitis (AD) and rheumatoid arthritis (RA) (12 arms), sponsored by Minghui Pharmaceutical, Inc. Primary endpoints: Treatment-Emergent Adverse Events at 1 year, Maximum Tolerated Dose at 1 year and 1 more. Status: unknown.
02
Drugs
INN-04-01
03
Conditions
atopic dermatitis (AD)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04815148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04815148.